The present disclosure features compositions and methods for the treatment of bacterial infections, such as bacterial infections caused by bacterial cells residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering antimicrobial agents to specifically target the intracellular compartment (endosome, phagosome, lysosome, or cytosol) in which the bacterial cell resides.

The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R.sup.1 is halogen, OH, or —OC(O)C1-5alkyl, R.sup.2 and R.sup.3 are each independently selected from CO2R.sup.4 and CH2OR.sup.5; R.sup.4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R.sup.5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

##STR00001##

The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R.sup.1 is halogen, OH, or —OC(O)C1-5alkyl, R.sup.2 and R.sup.3 are each independently selected from CO2R.sup.4 and CH2OR.sup.5; R.sup.4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R.sup.5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

##STR00001##

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.

The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.

The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.

This invention relates to use of a macrocyclic cavity-containing compound sensitizing a microbe towards an antimicrobial agent. The invention also relates to use of a macrocyclic cavity-containing compound in reducing the amount of an antimicrobial agent needed to prevent or inhibit the growth of a microbe in a subject. Further, the invention relates to use of a macrocyclic cavity-containing compound in reducing the build-up of resistance of a microbe towards an anti-microbial agent. The invention also relates to a macrocyclic cavity-containing compound and an antimicrobial agent for use in inhibiting/treating/preventing a microbial infection in a subject having a microbial infection or being at risk of a microbial infection.